Design of Anticancer Lysophosphatidic Acid Agonists and Antagonists

References

• Mutoh T , RiveraR, ChunJ. Insights into the pharmacological relevance of lysophospholipid receptors. Br. J. Pharmacol.165 (4), 829–844 (2012).
   PubMed Web of Science ®Google Scholar
• Parrill AL , TigyiG. Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions. Biochim. Biophys. Acta1831 (1), 2–12 (2013).
   PubMed Web of Science ®Google Scholar
• Brindley DN , LinFT, TigyiGJ. Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim. Biophys. Acta1831 (1), 74–85 (2013).
   PubMed Web of Science ®Google Scholar
• Moolenaar WH , PerrakisA. Insights into autotaxin: how to produce and present a lipid mediator. Nat. Rev. Mol. Cell Biol.12 (10), 674–679 (2011).
   PubMed Web of Science ®Google Scholar
• Umezu-Goto M , KishiY, TairaAet al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol.158 (2), 227–233 (2002).
   PubMed Web of Science ®Google Scholar
• Tokumura A , MajimaE, KariyaYet al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem.277 (42), 39436–39442 (2002).
   PubMed Web of Science ®Google Scholar
• Hiramatsu T , SonodaH, TakanezawaYet al. Biochemical and molecular characterization of two phosphatidic acid-selective phospholipase A1s, mPA-PLA1alpha and mPA-PLA1beta. J. Biol. Chem.278 (49), 49438–49447 (2003).
   PubMed Web of Science ®Google Scholar
• Foell JL , HesseM, VolkmerI, SchmiedelBJ, NeumannI, StaegeMS. Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumour-associated cancer/testis antigen. Pediatr Blood Cancer51 (2), 228–234 (2008).
   PubMed Web of Science ®Google Scholar
• Schmiedel BJ , HutterC, HesseM, StaegeMS. Expression of multiple membrane-associated phospholipase A1 beta transcript variants and lysophosphatidic acid receptors in Ewing tumor cells. Mol. Biol. Rep.38 (7), 4619–4628 (2011).
   PubMed Web of Science ®Google Scholar
• Yung YC , StoddardNC, ChunJ. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J. Lipid Res. doi:10.1194/jlr.R046458 (2014) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Lv GM , LiP, WangWD, Wang ShK, ChenJF, GongYL. Lysophosphatidic acid (LPA) and endothelial differentiation gene (Edg) receptors in human pancreatic cancer. J. Surg. Oncol.104 (6), 685–691 (2011).
   PubMed Web of Science ®Google Scholar
• Gotoh M , FujiwaraY, YueJet al. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem. Soc. Trans.40 (1), 31–36 (2012).
   PubMedGoogle Scholar
• Willier S , ButtE, GrunewaldTG. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol. Cell105 (8), 317–333 (2013).
   PubMed Web of Science ®Google Scholar
• Schleicher SM , ThotalaDK, LinkousAGet al. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS ONE6 (7), e22182 (2011).
   PubMed Web of Science ®Google Scholar
• Samadi N , BekeleR, CapatosD, VenkatramanG, SariahmetogluM, BrindleyDN. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie93 (1), 61–70 (2011).
   PubMed Web of Science ®Google Scholar
• Houben AJ , MoolenaarWH. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev.30 (3–4), 557–565 (2011).
   PubMed Web of Science ®Google Scholar
• Okudaira S , YukiuraH, AokiJ. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie92 (6), 698–706 (2010).
   PubMed Web of Science ®Google Scholar
• Xu XY , PrestwichGD. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer Am. Cancer. Soc.116 (7), 1739–1750 (2010).
   Google Scholar
• Zhang H , XuX, GajewiakJet al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res.69 (13), 5441–5449 (2009).
   PubMed Web of Science ®Google Scholar
• Xu X , YangG, ZhangH, PrestwichGD. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Prostaglandins Other Lipid Mediat.89 (3–4), 140–146 (2009).
   PubMed Web of Science ®Google Scholar
• Komachi M , TomuraH, MalchinkhuuEet al. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis30 (3), 457–465 (2009).
   PubMed Web of Science ®Google Scholar
• Lee Z , ChengCT, ZhangHet al. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol. Biol. Cell19 (12), 5435–5445 (2008).
   PubMed Web of Science ®Google Scholar
• Jongsma M , Matas-RicoE, RzadkowskiA, JalinkK, MoolenaarWH. LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor. PLoS ONE6 (12), e29260 (2011).
   PubMed Web of Science ®Google Scholar
• Pan HL , ZhangYQ, ZhaoZQ. Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKC epsilon pathway in dorsal root ganglion neurons. Mol. Pain6, 85 (2010).
   PubMedGoogle Scholar
• Xiang SY , DusabanSS, BrownJH. Lysophospholipid receptor activation of RhoA and lipid signaling pathways. Biochim. Biophys. Acta1831 (1), 213–222 (2013).
   PubMed Web of Science ®Google Scholar
• Kitzing TM , SahadevanAS, BrandtDTet al. Positive feedback between Dia1, LARG, and RhoA regulates cell morphology and invasion. Genes Dev.21 (12), 1478–1483 (2007).
   PubMed Web of Science ®Google Scholar
• Shida D , KitayamaJ, YamaguchiHet al. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp. Cell Res.301 (2), 168–178 (2004).
   PubMed Web of Science ®Google Scholar
• Shida D , KitayamaJ, YamaguchiHet al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res.63 (7), 1706–1711 (2003).
   PubMed Web of Science ®Google Scholar
• Marshall JC , CollinsJ, MarinoN, SteegP. The Nm23-H1 metastasis suppressor as a translational target. Eur. J. Cancer46 (7), 1278–1282 (2010).
   PubMed Web of Science ®Google Scholar
• Peyruchaud O , LeblancR, DavidM. Pleiotropic activity of lysophosphatidic acid in bone metastasis. Biochim. Biophys. Acta1831 (1), 99–104 (2013).
   PubMed Web of Science ®Google Scholar
• Tager AM , LaCameraP, SheaBSet al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med.14 (1), 45–54 (2008).
   PubMed Web of Science ®Google Scholar
• Budd DC , QianY. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis. Future Med. Chem.5 (16), 1935–1952 (2013).
   PubMed Web of Science ®Google Scholar
• Ward Y , LakeR, MartinPLet al. CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. Oncogene32 (22), 2726–2738 (2013).
   PubMed Web of Science ®Google Scholar
• Ward Y , LakeR, YinJJet al. LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res.71 (23), 7301–7311 (2011).
   PubMed Web of Science ®Google Scholar
• Xu J , LaiYJ, LinWC, LinFT. TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J. Biol. Chem.279 (11), 10459–10468 (2004).
   PubMed Web of Science ®Google Scholar
• Willier S , ButtE, RichterGH, BurdachS, GrunewaldTG. Defining the role of TRIP6 in cell physiology and cancer. Biol. Cell103 (12), 573–591 (2011).
   PubMed Web of Science ®Google Scholar
• Lin S , WangD, IyerSet al. The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology136 (5), 1711–1720 (2009).
   PubMed Web of Science ®Google Scholar
• Lee SJ , YunCC. Colorectal cancer cells - proliferation, survival and invasion by lysophosphatidic acid. Int. J. Biochem. Cell Biol.42 (12), 1907–1910 (2010).
   PubMed Web of Science ®Google Scholar
• Deng W , BalazsL, WangDA, Van MiddlesworthL, TigyiG, JohnsonLR. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology123 (1), 206–216 (2002).
   PubMed Web of Science ®Google Scholar
• Kiss GN , LeeSC, FellsJIet al. Mitigation of radiation injury by selective stimulation of the LPA(2) receptor. Biochim. Biophys. Acta1831 (1), 117–125 (2013).
   PubMed Web of Science ®Google Scholar
• Hurst JH , HooksSB. Lysophosphatidic acid stimulates cell growth by different mechanisms in SKOV-3 and Caov-3 ovarian cancer cells: distinct roles for Gi- and Rho-dependent pathways. Pharmacology83 (6), 333–347 (2009).
   PubMed Web of Science ®Google Scholar
• Yu S , MurphMM, LuYet al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J. Natl Cancer Inst.100 (22), 1630–1642 (2008).
   PubMedGoogle Scholar
• Goldsmith ZG , HaJH, JayaramanM, DhanasekaranDN. Lysophosphatidic acid stimulates the proliferation of ovarian cancer cells via the gep proto-oncogene Galpha(12). Genes Cancer2 (5), 563–575 (2011).
   PubMedGoogle Scholar
• Pancione M , SabatinoL, FucciAet al. Epigenetic silencing of peroxisome proliferator-activated receptor gamma is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS ONE5 (12), e14229 (2010).
   PubMed Web of Science ®Google Scholar
• Tsukahara T , HanazawaS, KobayashiT, IwamotoY, Murakami-MurofushiK. Cyclic phosphatidic acid decreases proliferation and survival of colon cancer cells by inhibiting peroxisome proliferator-activated receptor gamma. Prostaglandins Other Lipid Mediat.93 (3–4), 126–133 (2010).
   PubMed Web of Science ®Google Scholar
• Endo T , KanoK, MotokiRet al. Lysophosphatidylmethanol is a pan lysophosphatidic acid receptor agonist and is produced by autotaxin in blood. J. Biochem.146 (2), 283–293 (2009).
   PubMed Web of Science ®Google Scholar
• Jiang G , InoueA, AokiJ, PrestwichGD. Phosphorothioate analogs of sn-2 radyl lysophosphatidic acid (LPA): metabolically stabilized LPA receptor agonists. Bioorg. Med. Chem. Lett.23 (6), 1865–1869 (2013).
   PubMed Web of Science ®Google Scholar
• Valentine WJ , FellsJI, PeryginDHet al. Subtype-specific residues involved in ligand activation of the endothelial differentiation gene family lysophosphatidic acid receptors. J. Biol. Chem.283 (18), 12175–12187 (2008).
   PubMed Web of Science ®Google Scholar
• Yanagida K , KurikawaY, ShimizuT, IshiiS. Current progress in non-Edg family LPA receptor research. Biochim. Biophys. Acta1831 (1), 33–41 (2013).
   PubMed Web of Science ®Google Scholar
• East JE , CarterKM, KennedyPCet al. Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist. MedChemComm2 (4), 325–330 (2011).
   PubMed Web of Science ®Google Scholar
• Durgam GG , ViragT, WalkerMDet al. Synthesis, structure–activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J. Med. Chem.48 (15), 4919–4930 (2005).
   PubMed Web of Science ®Google Scholar
• Fells JI , TsukaharaR, FujiwaraYet al. Identification of non-lipid LPA3 antagonists by virtual screening. Bioorg. Med. Chem.16 (11), 6207–6217 (2008).
   PubMed Web of Science ®Google Scholar
• Fells JI , TsukaharaR, LiuJ, TigyiG, ParrillAL. Structure-based drug design identifies novel LPA3 antagonists. Bioorg. Med. Chem.17 (21), 7457–7464 (2009).
   PubMed Web of Science ®Google Scholar
• Swaney JS , ChapmanC, CorreaLDet al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br. J. Pharmacol.160 (7), 1699–1713 (2010).
   PubMed Web of Science ®Google Scholar
• Qian Y , HamiltonM, SidduriAet al. Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts. J. Med. Chem.55 (17), 7920–7939 (2012).
   PubMed Web of Science ®Google Scholar
• Ren Y , GuoL, TangXet al. Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells. Microvasc. Res.85, 59–67 (2013).
   PubMed Web of Science ®Google Scholar
• Ohta H , SatoK, MurataNet al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol.64 (4), 994–1005 (2003).
   PubMed Web of Science ®Google Scholar
• Kiss GN , FellsJI, GupteRet al. Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol. Pharmacol.82 (6), 1162–1173 (2012).
   PubMed Web of Science ®Google Scholar
• Xu Y , JiangGW, TsukaharaR, FujiwaraY, TigyiG, PrestwichGD. Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors. J. Med. Chem.49 (17), 5309–5315 (2006).
   PubMed Web of Science ®Google Scholar
• Altman MK , GopalV, JiaWet al. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol. Cancer9, 140 (2010).
   Google Scholar
• Xue J , GanL, LiXet al. Effects of lysophosphatidic acid and its receptors LPA(1/3) on radiation pneumonitis. Oncol. Rep.24 (6), 1515–1520 (2010).
   PubMed Web of Science ®Google Scholar
• Gan L , XueJX, LiXet al. Blockade of lysophosphatidic acid receptors LPAR1/3 ameliorates lung fibrosis induced by irradiation. Biochem. Biophys. Res. Commun.409 (1), 7–13 (2011).
   PubMed Web of Science ®Google Scholar
• Swaney JS , ChapmanC, CorreaLDet al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J. Pharmacol. Exp. Ther.336 (3), 693–700 (2011).
   PubMed Web of Science ®Google Scholar
• Komachi M , SatoK, ToboMet al. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo. Cancer Sci.103 (6), 1099–1104 (2012).
   PubMed Web of Science ®Google Scholar
• David M , RibeiroJ, DescotesFet al. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int. J. Oncol.40 (4), 1133–1141 (2012).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov . clinicaltrials.gov
   Google Scholar
• Graber K . At the frontiers of lung fibrosis therapy. Nat. Biotech.31 (9), 781–783 (2013).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov: NCT01766817 . http://clinicaltrials.gov/show/NCT01766817
   Google Scholar
• ClinicalTrials.gov: NCT02068053 . http://clinicaltrials.gov/ct2/show/NCT02068053
   Google Scholar
• ClinicalTrials.gov: NCT02017730 . http://clinicaltrials.gov/ct2/show/NCT02017730
   Google Scholar
• ClinicalTrials.gov: NCT01651143 . http://clinicaltrials.gov/show/NCT01651143
   Google Scholar
• Vidot S , WithamJ, AgarwalRet al. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal.22 (6), 926–935 (2010).
   PubMed Web of Science ®Google Scholar
• Samadi N , BekeleRT, GopingIS, SchangLM, BrindleyDN. Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PLoS ONE6 (5), e20608 (2011).
   PubMed Web of Science ®Google Scholar
• Su SC , HuX, KenneyPAet al. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma. Clin. Cancer Res.19 (23), 6461–6472 (2013).
   PubMed Web of Science ®Google Scholar